Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ZCY vs CCM, CDIX, EHSI: Buyback Yield % Comparison
For the Medical Care Facilities subindustry, Cryo-Cell International's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International Buyback Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International (FRA:ZCY) has a Buyback Yield % of 0.00 as of Jul. 21, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cryo-Cell International and its competitors. Over the past decade, Cryo-Cell International's Buyback Yield % has ranged from 0.04 to 40.53. According to the industry distribution chart, Cryo-Cell International ranks #999999 out of 274 companies in the Healthcare Providers & Services industry.
Is Cryo-Cell International's Buyback Yield % too high?
Cryo-Cell International's current Buyback Yield % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 40.53. Based on the distribution chart, Cryo-Cell International ranks #999999 out of 274 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Cryo-Cell International has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's Buyback Yield % compare to CCM and CDIX?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #999999 out of 274 companies for Buyback Yield %. This places Cryo-Cell International in the lower half of its industry. Historically, Cryo-Cell International's own Buyback Yield % has ranged from 0.04 to 40.53 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cryo-Cell International and its competitors. Cryo-Cell International's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (FRA:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €4.44, compared to a current price of €2.80 — trading 36.9% below its estimated fair value. The current Buyback Yield % is 0.00. Cryo-Cell International's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Cryo-Cell International (FRA:ZCY), the current Buyback Yield % is 0.00 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (FRA:ZCY) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of €2.80 is trading 36.9% below its estimated GF Value™ of €4.44.
GuruFocus considers Cryo-Cell International to be Possible Value Trap.
Key valuation signals for FRA:ZCY:
Buyback Yield %: 0.00
GF Value™: €4.44 vs. price of €2.80 (36.9% below fair value)
No single metric tells the full story. See the FRA:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
65GF Score
Get the complete analysis for FRA:ZCY
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ZCY has been successfully added to your 
